What You Should Know:
- Quest Health Solutions, a national leader in diabetes care, today announced compelling results from its Remote Patient Monitoring (RPM) program, developed in partnership with the digital health company Rimidi. In just two months, the Quest Health RPM Services—powered by Rimidi's EHR-integrated platform—led to an 11% improvement in average blood glucose readings among participating patients.
- The collaboration highlights the power of combining
Read More
Impact of Diabetes Management for Patients, Payers, and Providers| News, Policy, Analysis, Insights - HIT Consultant
Glytec Secures $36M to Advance AI-Powered Diabetes Care and Inpatient Glycemic Management
What You Should Know:
- Glytec, a provider of an AI-powered technology platform for diabetes and related conditions, secures a $36M growth investment led by Savitr Capital and Hayfin Capital Management.
- The funding will fuel the continued expansion of Glytec’s platform, including its flagship Glucommander® SaaS solution, and accelerate the development of innovative new technologies. The investment comes as healthcare systems face increasing pressure to improve inpatient
Read More
Medtronic Rebrands Diabetes Business as “MiniMed” Ahead of Spin-Off
What You Should Know:
- Medtronic announced that its planned New Diabetes Company will be named MiniMed. The name honors the company's roots, reflecting its original name prior to its acquisition by Medtronic in 2001 and its deep, 40-year history of transforming diabetes care worldwide.
The announcement marks a significant step in the intended separation of Medtronic's Diabetes business into a new, independent entity.
Simplify Life with Diabetes
The new MiniMed's mission is to
Read More
Reach7 CEO Talks Reimagining Diabetes Care with Membership-Based Studio Clinics
Today’s landscape of diabetes care is fraught with challenges: it's a condition that's often misunderstood by both patients and the healthcare system, highly prevalent, financially burdensome and frequently mismanaged. To explore a new paradigm in addressing these issues, we're speaking with Chun Yong, the founder and CEO of Reach7 Diabetes Studios. Chun, a biomedical engineer from Georgia Tech with experience as a UX strategist at Coca-Cola, is applying his unique expertise to "reimagine how
Read More
LifeMD Launches $299 Introductory Wegovy® Bundle for Self-Pay Patients in Collaboration with Novo Nordisk
What You Should Know:
- LifeMD, Inc., a provider of virtual primary care services announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide).
- The comprehensive package includes both the GLP-1 medication and access to LifeMD’s virtual weight management program. The initiative is part of LifeMD's collaboration with Novo Nordisk, announced last month, and leverages a recently completed integration with NovoCare® Pharmacy to offer
Read More
Medtronic to Separate Diabetes Business into New Standalone Company
What You Should Know:
- Medtronic today announced its strategic decision to separate its Diabetes business into a new, independent, publicly traded company ("New Diabetes Company").
- The move aims to create a more focused Medtronic, with a simplified portfolio concentrated on high-margin growth markets, while simultaneously establishing a scaled, independent leader in the diabetes sector.
- The separation is expected to be completed within 18 months through a series of
Read More
Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR
What You Should Know:
- Abbott, a provider of continuous glucose monitoring (CGM) biowearable technology, has announced a landmark agreement with Epic Systems, a major provider of electronic health records (EHR).
- The first-of-its-kind collaboration for Abbott will integrate patient glucose data from its leading FreeStyle Libre CGM systems directly into Epic's EHR platform across the United States.
FreeStyle Libre Integration with Epic Aura
The integration leverages
Read More
Sequel twiist AID System to Integrate with Senseonics Eversense 365 One-Year CGM
What You Should Know:
- Sequel Med Tech, LLC, known for its innovative insulin delivery technology, and Senseonics Holdings, Inc., developer of long-term implantable continuous glucose monitoring (CGM) systems, announced a significant commercial development agreement.
- The collaboration will integrate Sequel's twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, with Senseonics' Eversense® 365 CGM system.
This partnership marks a notable advancement in diabetes
Read More
Eli Lilly’s Oral GLP-1 Shows Positive Trial Results for Type 2 Diabetes
What You Should Know:
- Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes whose blood sugar was inadequately controlled through diet and exercise alone.
- Orforglipron stands out as the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water restrictions, to successfully complete a Phase 3
Read More
FDA Clears Dexcom G7 15 Day Continuous Glucose Monitoring System
What You Should Know:
- Dexcom, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for individuals over the age of 18 with diabetes.
- The Dexcom G7 15 Day system boasts an overall Mean Absolute Relative Difference (MARD) of 8.0% and builds upon the proven performance of Dexcom CGM technology, which has been clinically demonstrated to lower A1C, reduce hyper- and hypoglycemia, and
Read More
